Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years

Annals of the Rheumatic Diseases

Volumn 73, Issue 11, 2014, Pages 1923-1928

  Baker, Joshua F ^a,b   Østergaard, Mikkel ^c,d   George, Michael ^b   Shults, Justine ^b   Emery, Paul ^e,f   Baker, Daniel G ^g   Conaghan, Philip G ^e,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; GOLIMUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BODY MASS; BONE MARROW DISEASES; COMPLICATION; DISEASE COURSE; EDEMA; FEMALE; FOLLOW UP; HAND JOINT; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; WRIST;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; BONE MARROW DISEASES; DISEASE PROGRESSION; EDEMA; FEMALE; FOLLOW-UP STUDIES; HAND JOINTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OVERWEIGHT; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; WRIST JOINT;

EID: 84921802224     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205544     Document Type: Article

References (23)

1. Westhoff G, Rau R, Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007;56:3575-82.
2. Kaufmann J, Kielstein V, Kilian S, et al. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 2003;30:2350-5.
3. Baker JF, George M, Baker DG, et al. Associations between body mass, radiographic joint damage, adipokines, and risk factors for bone loss in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:2100-7.
4. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, et al. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008;67:769-74.
5. Ajeganova S, Andersson ML, Hafstrom I. Obesity is associated with worse disease severity in rheumatoid arthritis as well as with co-morbidities-a long-term follow-up from disease onset. Arthritis Care Res (Hoboken) 2013;65:78-87.
6. Engvall IL, Tengstrand B, Brismar K, et al. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months. Arthritis Res Ther 2010;12:R197.
7. Conaghan PG, Ejbjerg B, Lassere M, et al. A multicenter reliability study of extremity-magnetic resonance imaging in the longitudinal evaluation of rheumatoid arthritis. J Rheumatol 2007;34:857-8.
8. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.
9. Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003;30:1385-6.
10. Baker JF, Ostergaard M, Emery P, et al. Early MRI measures independently predict 1-and 2-year X-ray progression: results from a large clinical trial. Ann Rheum Dis 2014;73:1968-74.
11. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
12. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
13. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
14. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-28.
15. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5.
16. Conaghan PG, Emery P, Ostergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74.
17. Baker JF, Conaghan PG, Smolen JS, et al. Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with MRI synovitis and X-ray progression. Arthritis Rheum 2014;66:794-802.
18. Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010;62:674-82.
19. Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011;63:3702-11.
20. Giles JT, Allison M, Bingham CO III, et al. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2009;61:1248-56.
21. Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 2011;70:1562-8.
22. Agholme F, Isaksson H, Li X, et al. Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats. Acta Orthop 2011;82:628-32.
23. Moustafa A, Sugiyama T, Prasad J, et al. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int 2012;23:1225-34.